＜4576＞ DWTI 201 +38

A surge. It was announced that the Rho kinase inhibitor ripasudil hydrochloride hydrate, which was developed, received approval in Thailand as a glaucoma and ocular hypertension treatment drug "Graalpha combination eye drops (domestic product name)" from its licensing partner Kowa, and this is seen as positive news. The drug has been on sale in Japan through Kowa since December 2022, and discussions for overseas sales were underway. This is the first time the drug has received approval overseas, and Kowa continues to consider further overseas expansion. Once the drug is launched in Thailand, the company will receive royalties based on its contract with Kowa.

＜6085＞ Akitects SJ 433 +18

A significant rebound. It was announced that all Stocks of MED would be acquired and made a consolidated subsidiary. MED is a company with an excellent track record and know-how in digital marketing, and its main business activities include building media that expands and constructs customer touchpoints through the formulation of digital marketing strategies, building an operational structure that accumulates knowledge to improve accuracy, digital marketing operations, digital branding and creative work, and advertising agency work specialized in the digital field. It has been determined that this is the ideal company to handle the in-house operations of the company's digital field.

＜7067＞ Branding 1638 +300

Limit up. After the market closed on the 25th, it was announced that a capital and business alliance had been formed with Japan Asia Investment, and it seems to be viewed as favorable. Japan Asia Investment is supporting financing for its client network, which includes investment destinations and investment considerations for a limited liability partnership aimed at small and medium-sized enterprises facing business succession issues in Japan, managed in collaboration with other companies, while the company aims to promote the growth of these companies by providing support for value enhancement of investments through branding and marketing assistance.

＜4011＞ Headwater 5890 +640

There was a sharp rebound, temporarily reaching the limit up. It was announced that a service for visualizing AI agent operations and Consulting Services has been launched for companies considering the introduction of AI agents. While the introduction of AI agents can be expected to enhance operational efficiency and productivity, an increasing number of companies are facing the challenge of determining which operations to adopt them in. As the range of operations conducted by companies becomes broader and more complex, determining the appropriate introduction points for AI agents is not easy. The company has launched Consulting Services to accurately grasp the current state of operations and maximize the effects of AI agent implementation.

<2164> Local newspaper company 327 -18

Sharp decline. Announced the results for the first quarter of the fiscal year ending in August 2025, showing that ordinary profit dropped 54.1% year-on-year to 5 million yen, which seems to have caused concern. However, revenue was steady, increasing by 4.5% year-on-year to 0.788 billion yen. Overall advertising-related business continues to see high demand for advertising to attract customers, maintaining a recovery trend. In the "Chiki Newspaper" publishing business related to newspaper publishing, the policy of concentrating sales resources on acquiring major L clients to improve customer unit price continues, and segments such as repair services, purchasing services, and seminar announcements continue to show high demand.

<4597> Soleirja 36 -1

Decline. After the close of trading on the 27th, it was announced that the full-year performance forecast for the fiscal year ending December 2024 was revised downwards, leading to an initial Sell. The revenue was reduced by 1.09 billion yen from the previous forecast value (lower limit) to 0.16 billion yen. Although the sales partner had anticipated completing the shipment of inventory around mid-year, in reality, the shipments have Stunk, resulting in a low shipment volume of new facility manufactured products for this year as well. Additionally, the reason includes the inability to realize the rights derivation for Dalbivias in China, which had been a premise for the previous performance forecast, leading to the exclusion of the expected contract lump sum revenue from the current revenue forecast.